←
Kat183 posts
Kat avatar

Kat

@katyenko

building @muni_bio AI ∩ bio | in vitro to in silico, always an experimenter

◷ Joined August 2024▧ 28 Photos and videos
Kat avatar
Kat@katyenko·Oct 30

Binding is nice, but it’s getting boring. If you’re not thinking about biological function, you’re ngmi. At our last @muni_bio hackathon co-hosted with @onepot_ai, we set one ambitious goal: neutralize the latest threat of Ebola using small molecules. The wet lab data is in, and we’re excited to announce that teams were successful, including our agent that repurposed... an anti-itch gel?
 muni.bio/research/hits-from-…

Emma avatar
⟳ Kat retweeted
Emma@emmamariecryer·Nov 2

coolest email i have gotten since starting at @OpenRouter: "the compute you sponsored helped identify hits against Bundibugyo ebolavirus in our assays" you check out what @katyenko and her team were able to accomplish here:

Kat@katyenkoOct 30

Binding is nice, but it’s getting boring. If you’re not thinking about biological function, you’re ngmi. At our last @muni_bio hackathon co-hosted with @onepot_ai, we set one ambitious goal: neutralize the latest threat of Ebola using small molecules. The wet lab data is in, and we’re excited to announce that teams were successful, including our agent that repurposed... an anti-itch gel?
 muni.bio/research/hits-from-…

Gabriele Corso avatar
⟳ Kat retweeted
Gabriele Corso@GabriCorso·Oct 30

Great to see teams using the Boltz API at the Ebolathon successfully designing novel molecules! 140 molecules tested, 11 selective hits in Ebola pseudovirus assays. Exciting to see hackathon ideas turn into experimental results! 🧪 muni.bio/research/hits-from-…

Derek Alia avatar
⟳ Kat retweeted
Derek Alia@derekalia·Oct 30

The factorioization of biology is happening. Expect faster/cheaper experimental validation and more novel drugs developed at a fraction of todays cost. My sense is that many people inside the drug development industry are further behind in understanding what's becoming possible than those on the outside looking in. Which leads to an interesting arbitrage, bound purely by ambition. Teams that embrace agentic workflows will soon look like an entirely different species of biotech, one that the old guard will struggle to comprehend. Some will interpret this negatively as the removal of human creativity from biological research, my view is opposite. I think this gives people with deep biological insight far more leverage. Freeing them from the tedious, repetitive work that consumes most of their context. Exciting times.

Kat@katyenkoOct 30

Binding is nice, but it’s getting boring. If you’re not thinking about biological function, you’re ngmi. At our last @muni_bio hackathon co-hosted with @onepot_ai, we set one ambitious goal: neutralize the latest threat of Ebola using small molecules. The wet lab data is in, and we’re excited to announce that teams were successful, including our agent that repurposed... an anti-itch gel?
 muni.bio/research/hits-from-…

Modal avatar
⟳ Kat retweeted
Modal@modal·Oct 30

In July, @muni_bio and @onepot_ai co-hosted Ebolathon to find small molecules that could block Bundibugyo ebolavirus from entering cells without harming the cells themselves. Teams designed 140 molecules in just one Saturday in San Francisco. All were synthesized in 11 lab days, followed by 22 lab days of testing. The results are in: 26 of the 140 molecules were preliminary hits—an 18.6% hit rate. In part, powered by Modal.

Kat@katyenkoOct 30

Binding is nice, but it’s getting boring. If you’re not thinking about biological function, you’re ngmi. At our last @muni_bio hackathon co-hosted with @onepot_ai, we set one ambitious goal: neutralize the latest threat of Ebola using small molecules. The wet lab data is in, and we’re excited to announce that teams were successful, including our agent that repurposed... an anti-itch gel?
 muni.bio/research/hits-from-…

Kat avatar
Kat@katyenko·Oct 30

A huge thank you to @PostHog for hosting us, and to @RowanSci, @boltz_bio, @modal, @OpenRouter, and @anyscalecompute for the computational resources and support throughout. Also, @derekalia, @daniil_boiko, @andrei_tyrin, & @CorinWagen for making this happen. And to everyone who spent their Saturday designing molecules with us. Getting to share the lab results is the best part :) Mission complete: x.com/katyenko/status/206763…

Kat@katyenkoJun 18

EBOLATHON - the ultimate rapid-response challenge against viral threats. 8 hours to generate and submit compounds to test against Bundibugyo Ebola strain with wet-lab validation. Join us in SF on July 18th: luma.com/2rbgfn69 Hosted by @muni_bio & @onepot_ai

0:06
Kat avatar
Kat@katyenko·Oct 30

The next drug discovery team will be a few scientists, a team of agents, and a network of CROs. This is the world we’re building with muni (muni.bio/dispatch).
 As models more accurately predict binders, the question becomes, “does this binder actually do what we want?” Cost and speed of function, ADME, PK and tox assays will set the pace of discovery. We’re betting that early and iterative work will go to CROs that are fast, rigorous, and transparent, and ready to work with agents. A solo drug hunter should be able to run a program without building an entire lab. h/t @Prof_Oak_ for leading the charge.

Kat avatar
Kat@katyenko·Oct 30

Human-led team, core-or-bust, led the leaderboard with a tamoxifen series, but @grok on the muni harness stayed competitive with a repurposed cough suppressant. An attempt to use @AnthropicAI and @OpenAI models was made, but the guardrails were too strong and rendered our efforts futile.

Post attachment
Kat avatar
Kat@katyenko·Oct 30

140 compounds were submitted as ANTIviral candidates, synthesized by onepot in 11 days, and tested. We ended up with 26 preliminary hits, or an 18.6% hit rate.

Post attachment
Patrick Collison avatar
⟳ Kat retweeted
Patrick Collison@patrickc·Oct 27

A2A payments will be more important than P2P payments.

Stripe@stripeOct 27

Introducing 'stripe pay', for instant business-to-business transfers. Find companies using their Stripe profile handle and send funds for free. Available in the Dashboard and CLI.

0:23
Kat avatar
Kat@katyenko·Oct 22

expect more of this

In January 2025 my mom’s lung cancer spread to her brain. The drug with the best chance of helping her was approved in China but not here. A doctor told me, almost as an aside, that if she were Chinese she could buy it at a pharmacy. So I flew to Shanghai and came home with 26 boxes in my luggage. That was 19 months ago. My mom is still here, still working, and in her words has had an amazing three years. The drug was approved in China in 2023. The FDA approved it in July 2025. It still is not for sale here. I know of at least 30 Americans who have made the same trip. I have been scared to tell this story because I worried it could cost my mom access to the medicine keeping her alive. But the problem matters more than my silence. These drugs need to be developed and available here, and that means FDA reform. Art Allen at KFF Health News told our story this week. It also ran in The Washington Post. kffhealthnews.org/health-ind…

Tim Duignan avatar
⟳ Kat retweeted
Tim Duignan@TimothyDuignan·Oct 21

Force fields and folding models finally merging, nice

The latent space is physics-informed: we train on physics-based data (synthetic PDB with glycan conformers, DFT small molecules from OMol) and supervise the autoencoder with force-field backprop via TMol (more soon!). New tasks then just need new input conditions. 5/30

Post attachment
nahu avatar
⟳ Kat retweeted
nahu@tkisrage·Oct 10

Worse than actual gore

0:20
Kat avatar
Kat@katyenko·Sep 29

a kat-permutation authorship publishing a paper with hand-drawn dinosaurs over plots <3

This tweet is unavailable

Corin Wagen avatar
⟳ Kat retweeted
Corin Wagen@CorinWagen·Sep 22

We're launching 30B-scale virtual screening at Rowan today in partnership with @onepot_ai. By combining Rowan's high-throughput computational infrastructure with onepot's autonomous lab, we can go from target to experimental data in weeks, not months.

Post attachment
James Sinka - Boston & SF avatar
⟳ Kat retweeted
James Sinka - Boston & SF@jamessinka·Sep 22

Excited to introduce @ReactorfieldAI Cohort 1: @merge - brain-computer interfaces with no implants, $250M seed led by OpenAI and Bain @episteme - a new R&D institution, cofounded by Louis Andre and Sam Altman @RetroBio_ - unicorn longevity startup, adding 10 healthy years to human life. In phase 1 trials @NorthwellHealth - NY's largest healthcare system, with Chief Biotech Officer @itchdoctor @StrandTx - programmable mRNA medicines out of MIT, lead cancer drug already in patients @MayoClinic - turning leading clinical science into new ventures represented by @vera_mucaj @xiliotx - publicly traded biotech making cancer therapies to activate inside tumors @marathonfusion - producing the world's most valuable isotopes from compact fusion reactors @KopraBio - viruses that turn cancer cells into factories for their own destruction @radifymetals - hydrogen-plasma reactors that turn rare-earth oxides directly into metal @FoundationManf - rapid domestic CNC machining for frontier hardware @MassMagnetics - US-made high-performance magnets from recycled rare earths @algabiosciences - turning cattle methane into calories, peer-reviewed cuts of up to 63% @lumehealth - building a wearable that measures cortisol continuously from sweat @liu_liu_lemon - smart materials for med tech and robotics, @Harvard PhD, Fulbright Fellow

Post attachment

AI transformed coding, science is next @ReactorfieldAI makes scientists and deep tech startups AI-native Built by me and @berkbuilds to accelerate science with frontier AI

2:07